Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 258-264

  Marshall, Gary S ^a   Marchant, Colin D ^b   Blatter, Mark ^c   Friedland, Leonard R ^d   Aris, Emmanuel ^e   Miller, Jacqueline M ^d  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c Primary Physicians Research   (United States)

^d GLAXOSMITHKLINE   (United States)

^e GSK   (Belgium)

Author keywords

Co administration; DTaP HepB IPV vaccine; Haemophilus influenzae type b; Neisseria meningitidis serogroups C and Y; Pneumococcal conjugate vaccine; Vaccination

Indexed keywords

BACTERIAL VACCINE; BACTERIUM ANTIBODY; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE PLUS TETANUS TOXOID; HEPATITIS B SURFACE ANTIGEN; PERTUSSIS ANTIBODY; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VIRUS ANTIBODY; STREPTOCOCCUS PNEUMONIAE ANTIBODY; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFANT; MULTICENTER STUDY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; INFANT; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; PERTUSSIS VACCINE; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; SINGLE-BLIND METHOD; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 79952459565     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.14170     Document Type: Article

References (30)

1. Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians. MMWR Recomm Rep 1999; 48:1-14.
2. National Vaccine Advisory Committee. Standards for child and adolescent immunization practices. National Vaccine Advisory Committee. Pediatrics 2003; 112:958-63.
3. Kroger AT, Sumaya CV, Pickering LK, Atkinson WL. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011;60:1-58.
4. th Edition. Washington DC: Public Health Foundation 2009.
5. Happe LE, Lunacsek OE, Kruzikas DT, Marshall GS. Impact of a pentavalent combination vaccine on immunization timeliness in a state Medicaid population. Pediatr Infect Dis J 2009; 28:98-101.
6. Pöllabauer EM, Petermann R, Ehrlich HJ. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 2009; 27:1674-9.
7. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008; 8:435-43.
8. Centers for Disease Control and Prevention (CDC). Progress toward elimination of Haemophilus influenzae type b disease among infants and children - United States 1987-1993. MMWR Morb Mortal Wkly Rep 1994; 43:144-8.
9. Centers for Disease Control and Prevention (CDC). Continued shortage of Haemophilus influenzae type b (Hib) conjugate vaccines and potential implications for Hib surveillance - United States 2008. MMWR Morb Mortal Wkly Rep 2008; 57:1252-5.
10. Centers for Disease Control and Prevention (CDC). Invasive Haemophilus influenzae type b disease in five young children - Minnesota 2008. MMWR Morb Mortal Wkly Rep 2009; 58:58-60.
11. Oh SY, Griffiths D, John T, Lee YC, Yu LM, McCarthy N, et al. School-aged children: a reservoir for continued circulation of Haemophilus influenzae type b in the United Kingdom. J Infect Dis 2008; 197:1275-81.
12. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
13. Marchant CD, Miller JM, Marshall GS, Blatter M, Aris E, Friedland LR, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2010; 29:48-52.
14. Marshall GS, Marchant CD, Blatter M, Aris E, Boutriau DR, Poolman JT, et al. Immune response and one year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neiserria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12-15 months of age. Pediatr Infect Dis J 2010; 29:469-71.
15. Darkes MJ, Plosker GL. Pneumococcal conjugate vaccine (Prevnar; PNCRM7): a review of its use in the prevention of Streptococcus pneumoniae infection. Paediatr Drugs 2002; 4:609-30.
16. Hsu KK, Pelton SI. Heptavalent pneumococcal conjugate vaccine: current and future impact. Expert Rev Vaccines 2003; 2:619-31. (Pubitemid 37295361)
17. Yeh SH. PEDIARIX: clinical trials. Expert Rev Vaccines 2005; 4:139-45.
18. Nolan T, Lambert S, Roberton D, Marshall H, Richmond P, Streeton C. DTPa-HBV-IPV vaccine for primary vaccination of infants. J Paediatr Child Health 2007; 43:587-92. (Pubitemid 47222689)
19. Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66:2093-8. (Pubitemid 28194107)
20. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67.
21. Barra A, Schultz D, Aucouturier P. Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISA. J Immunol Methods 1988; 115:111-7.
22. Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984; 20:772-4. (Pubitemid 14006079)
23. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-44. (Pubitemid 13053038)
24. Sato Y, Sato H, Izumiya K, Conwell JL, Manclark CR. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. In: Robbins JB, Hill JC, Sardoff JC, Eds. Seminars in Infectious Disease: Bacterial Vaccines. New-York: Thierne-Stratton Inc 1982; 380-5.
25. Granström M, Thorén M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987; 6:18-21. (Pubitemid 17034613)
26. Frisch-Niggemeyer W, Ambrosch F, Hofmann H. The assessment of immunity against hepatitis B after vaccination. J Biol Stand 1986; 14:255-8. (Pubitemid 16018390)
27. Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1981; 1:377-85.
28. Concepcion N, Frasch C. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001; 8:266-72. (Pubitemid 32217054)
29. Henckaerts I, Goldblatt D, Ashton L, Poolman J. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with 19 or without 22F inhibition at low antibody concentrations in pediatric sera. Clin Vaccine Immunol 2006; 13:356-60.
30. World Health Organization. Standard procedure for determining immunity to poliovirus using the microneutralization test 1993; WHO/EPI/Gen 93.9.